Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication
| Autor: | Omar Abdel-Rahman Ali, Glenn Dranoff, Sarah A. Lewin, David J. Mooney |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Cancer Research Combination therapy Programmed Cell Death 1 Receptor Immunology Melanoma Experimental chemical and pharmacologic phenomena Biology Cancer Vaccines Article Immunomodulation Mice 03 medical and health sciences Lymphocytes Tumor-Infiltrating 0302 clinical medicine Neoplasms Tumor regression medicine Animals Immunologic Factors Cytotoxic T cell CTLA-4 Antigen Melanoma Antibodies Monoclonal hemic and immune systems medicine.disease Immune checkpoint Disease Models Animal CTL 030104 developmental biology 030220 oncology & carcinogenesis biology.protein Female Cancer vaccine Antibody T-Lymphocytes Cytotoxic |
| Zdroj: | Cancer Immunology Research. 4:95-100 |
| ISSN: | 2326-6074 2326-6066 |
| Popis: | We demonstrate that a poly(lactide-co-glycolide) (PLG) cancer vaccine can be used in combination with immune checkpoint antibodies, anti–CTLA-4 or anti–PD-1, to enhance cytotoxic T-cell (CTL) activity and induce the regression of solid B16 tumors in mice. Combination therapy obviated the need for vaccine boosting and significantly skewed intratumoral reactions toward CTL activity, resulting in the regression of B16 tumors up to 50 mm2 in size and 75% survival rates. These data suggest that combining material-based cancer vaccines with checkpoint antibodies has the potential to mediate tumor regression in humans. Cancer Immunol Res; 4(2); 95–100. ©2015 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|